Deka Biosciences
Deka Biosciences is an innovative biotechnology company focused on developing targeted cytokine therapies for cancer and inflammatory diseases. Their platform, Diakine™, utilizes paired cytokines and advanced targeting systems to enhance immune response and reduce toxicity. The company emphasizes personalized medicine, leveraging genetic and biomarker insights to tailor treatments. Led by a team of experienced industry veterans and supported by a scientific advisory board comprising global experts, Deka is committed to advancing clinical trials and expanding its pipeline of cytokine-based therapeutics.
Industries
Nr. of Employees
small (1-50)
Deka Biosciences
Patents
Products
EGFR‑directed multi‑cytokine fusion therapeutic (early clinical)
A targeted single‑chain multi‑cytokine fusion therapeutic in first‑in‑human Phase I evaluation for EGFR‑expressing solid tumors; combines stimulatory and anti‑inflammatory cytokine domains with a targeting scFv to enhance tumor localization and modulate systemic immune activation.
Tissue‑directed anti‑inflammatory multi‑cytokine therapeutic (preclinical)
Preclinical constructs combining multiple anti‑inflammatory cytokine domains with scFv‑based targeting to enrich inflamed tissues for localized treatment of autoimmune and inflammatory diseases (examples include gastrointestinal, dermatologic, and rheumatologic indications).
Diakine™
Proprietary targeted cytokine fusion protein platform designed to control toxic inflammation while potently activating the immune system.
Diakine™- DKIFN-α 10 (EGFR)
Diakine™ therapeutic featuring IFN-α and high affinity IL-10 targeting EGFR.
Diakine™- DK1210 (EGFR)
Diakine™ therapeutic featuring IL-12 and high affinity IL-10 targeting EGFR.
Diakine™- DK710 (EGFR)
Diakine™ therapeutic featuring IL-7 and high affinity IL-10 targeting EGFR.
EGFR‑directed multi‑cytokine fusion therapeutic (early clinical)
A targeted single‑chain multi‑cytokine fusion therapeutic in first‑in‑human Phase I evaluation for EGFR‑expressing solid tumors; combines stimulatory and anti‑inflammatory cytokine domains with a targeting scFv to enhance tumor localization and modulate systemic immune activation.
Tissue‑directed anti‑inflammatory multi‑cytokine therapeutic (preclinical)
Preclinical constructs combining multiple anti‑inflammatory cytokine domains with scFv‑based targeting to enrich inflamed tissues for localized treatment of autoimmune and inflammatory diseases (examples include gastrointestinal, dermatologic, and rheumatologic indications).
Diakine™
Proprietary targeted cytokine fusion protein platform designed to control toxic inflammation while potently activating the immune system.
Diakine™- DKIFN-α 10 (EGFR)
Diakine™ therapeutic featuring IFN-α and high affinity IL-10 targeting EGFR.
Diakine™- DK1210 (EGFR)
Diakine™ therapeutic featuring IL-12 and high affinity IL-10 targeting EGFR.
Diakine™- DK710 (EGFR)
Diakine™ therapeutic featuring IL-7 and high affinity IL-10 targeting EGFR.
Services
Co‑development, licensing and external collaboration to advance targeted multi‑cytokine fusion therapeutics and companion diagnostic assays.
Co‑development, licensing and external collaboration to advance targeted multi‑cytokine fusion therapeutics and companion diagnostic assays.
Expertise Areas
- Immuno‑oncology drug discovery
- Inflammation and autoimmune therapeutic development
- Protein engineering and fusion biologic design
- Biomarker‑driven precision medicine
Key Technologies
- Single‑chain multi‑cytokine fusion proteins
- Affinity‑modified cytokine variants
- Low‑affinity cytokine engineering
- scFv targeting scaffolds
News & Updates
Deka Biosciences announced the commencement of construction on a new facility to support its expanding pipeline of cytokine therapeutics, emphasizing its growth and commitment to innovation.
An article discussing the roots and evolution of immuno-oncology, highlighting how the field has developed from the late 19th century to modern therapies.
Deka Biosciences announced the commencement of construction on a new facility to support its expanding pipeline of cytokine therapeutics, emphasizing its growth and commitment to innovation.
An article discussing the roots and evolution of immuno-oncology, highlighting how the field has developed from the late 19th century to modern therapies.